J&J agrees to acquire Ollin for up to $3.4B

Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront, with additional regulatory and commercial milestone payments possible. The deal would add OLN324, an experimental bispecific antibody targeting pathways involved in retinal disease, to J&J’s pipeline. Ollin is developing the drug for wet age-related macular degeneration and diabetic macular edema; J&J also plans a separate funding agreement with Blackstone Life Sciences to support OLN324’s Phase 3 development, contingent on the acquisition closing.






